Disrupting cancer through SurVaxM immunotherapy
At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients
News and Events
MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients
New clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK) in recurrent glioblastoma patients.
May 30, 2020
MimiVax to present results of SurVaxM in glioblastoma at ASCO 2019 Meeting
Updated median progression free survival (mPFS) is 15.5 months from diagnosis. Median overall survival (OS) is at 30.5 months from diagnosis. SurVaxM immunotherapy generated encouraging efficacy and immunogenicity in glioblastoma with minimal toxicity.
June 05, 2019
Mimivax looks for game-changer in GBM as SurVaxM shows signal at interim look
In the ongoing study, survival trends strengthened as the data have matured. With the phase II in nGBM so far achieving a survival rate that exceeds the historical standard of care by 40 percent, the study already met its six-month PFS endpoint.
May 21, 2018
MimiVax
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
PartnerING
MimiVax is improving outcomes and quality of life for those suffering from devastating diseases as well as strengthening the biomedical startup ecosystem of Buffalo, New York.
Pipeline
We’re exploring new ways of stimulating the immune system to fight cancer cells leveraging our proprietary survivin-targeting technology.
Clinical Trials
SurVaxM is presently being studied in glioblastoma (newly diagnosed and recurrent), multiple myeloma and neuroendocrine tumors (NET).
“The Jacobs family has a deep passion for the discovery of new drugs and medical devices that will help ease the suffering and offer improved treatments for patients diagnosed with chronic and terminal diseases.”
Our History
OUR MISSION
To disrupt cancer with innovative immunotherapies
SurVaxM is currently being evaluated in: a Phase II clinical trial in adults with newly diagnosed glioblastoma; a Phase I clinical trial in combination with REVLIMID® (lenalidomide) for adults with multiple myeloma; and a Phase I clinical trial for metastatic neuroendocrine tumors (NET).
Disrupt cancer with the development of highly innovative immunotherapies
Partner with us
MimiVax is a privately held, clinical-stage biotechnology company that was formed in 2012 from Roswell Park Comprehensive Cancer Center. This was quickly followed by a prestigious award from the American Cancer Society, and support from the Roswell Park Alliance Foundation enabling clinical studies of SurVaxM for glioblastoma. If you are an investor interested in MimiVax, please reach out via the contact form below.
MimiVax is a team of experienced scientists, leading clinicians and industry leaders.
We are committed to pursuing the most efficient and comprehensive path to deliver upon the promise of SurVaxM to improve the lives of those battling cancer.
Contact us
Help accelerate the pace of SurvaxM clinical trials
The Roswell Park Alliance Foundation is the charitable arm of Roswell Park Comprehensive Cancer Center, where SurVaxM research started. Donations to the Alliance Foundation helped make early phase SurVaxM clinical studies possible and will continue to accelerate the pace and scope of future SurVaxM clinical trials. Please follow this link to make a potentially life changing contribution to this critical effort.